The Effectiveness of Tumor Necrosis Factor α Antibody (Infliximab) in Treating Recalcitrant Psoriasis

Abstract

A single infusion of infliximab at 5 to 10 mg/kg resulted in the rapid and complete clearing of recalcitrant psoriatic plaques and erythroderma with a disease-free interval of 3 to 4 months in these 2 patients and improved the symptoms of psoriatic arthritis.